NCT06498297

Brief Summary

Confusion syndrome is defined by attentional disorders and disorganization of cognitive functions that are acute and reversible. There are patient-specific predisposing factors and precipitating factors. Elderly people, due to their comorbidities, are more at risk. Confusion syndrome affects approximately 23% of elderly patients in the medical department, 33% in the rehabilitation department and its occurrence is preventable in 30 to 40% of cases. The health expenditure generated by its occurrence was estimated at 182 billion dollars per year by combining the expenditure of 18 European countries in 2011. The occurrence of a delirium increases the duration of hospitalization, increases the risk of falls, loss of autonomy, can lead to an impairment of quality of life at 6 months and is linked to excess mortality. The gold standard for making the diagnosis of delirium is the use of the DSM-5 criteria, but their use is time-consuming and requires that staff be trained in their use. The 4 "A" test (tool to help identify confusional syndrome) can be used to monitor confusional syndromes; it has the advantage of being able to be taken in less than 3 minutes. Concerning the management of a confusional syndrome, a non-pharmacological multi-component approach is recommended as first line for its prevention but there is no treatment to date. A tool to help with temporo-spatial reorientation (La Rob'Gazette) has been set up in the Medical Care and Geriatric Rehabilitation (SMRG) departments of the HUS

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
500

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Oct 2023

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 24, 2023

Completed
8 months until next milestone

First Submitted

Initial submission to the registry

July 4, 2024

Completed
8 days until next milestone

First Posted

Study publicly available on registry

July 12, 2024

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2025

Completed
23 days until next milestone

Study Completion

Last participant's last visit for all outcomes

April 24, 2025

Completed
Last Updated

July 12, 2024

Status Verified

July 1, 2024

Enrollment Period

1.4 years

First QC Date

July 4, 2024

Last Update Submit

July 4, 2024

Conditions

Keywords

Attention DisorderConfusion syndromeAttentional disordersDisorganization of cognitive functions

Outcome Measures

Primary Outcomes (1)

  • Speed of improvement of the 4AT of the entire population

    The analysis will be undertaken on patients for whom at least two 4AT measurements are available (in order to be able to calculate a change). It will be based on a mixed linear model including the variable to be tested, time and their interaction. Variables deemed clinically relevant or statistically significant at the threshold of p \< 0.10 will be included in a multivariate model. Then the non-significant and irrelevant variables will be removed from the model. The significance threshold will be 0.05 for this final model.

    Up to 2 years

Eligibility Criteria

Age75 Years+
Sexall
Healthy VolunteersNo
Age GroupsOlder Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patient aged 75 and over hospitalized at the HUS in the SMRG department during the period from January 1, 2021 to April 31, 2023 and havin passed at least a 4AT during hospitalization.

You may qualify if:

  • Patient aged 75 and over
  • Hospitalized at the HUS in the SMRG department during the period from January 1, 2021 to April 31, 2023
  • Passed at least a 4AT during hospitalization
  • Absence of written opposition in the patient's medical file (and/or their legal representative if applicable) to the reuse of their data for scientific research purposes.

You may not qualify if:

  • \- Presence of written opposition from the patient (and/or their legal representative if applicable) in their medical file.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Service de Soins de Soins Médicaux et de Réadaptation - CHU de Strasbourg - France

Strasbourg, 67091, France

RECRUITING

MeSH Terms

Conditions

Cognition Disorders

Condition Hierarchy (Ancestors)

Neurocognitive DisordersMental Disorders

Central Study Contacts

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 4, 2024

First Posted

July 12, 2024

Study Start

October 24, 2023

Primary Completion

April 1, 2025

Study Completion

April 24, 2025

Last Updated

July 12, 2024

Record last verified: 2024-07

Locations